{"id":155991,"date":"2021-09-22T11:09:51","date_gmt":"2021-09-22T09:09:51","guid":{"rendered":"https:\/\/clinical.r-biopharm.com\/?p=155991"},"modified":"2021-09-22T11:09:46","modified_gmt":"2021-09-22T09:09:46","slug":"update-therapeutisches-drug-monitoring-fuer-vedolizumab","status":"publish","type":"post","link":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/","title":{"rendered":"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab"},"content":{"rendered":"<div class=\"wpb-content-wrapper\">[vc_row][vc_column][vc_row_inner][vc_column_inner][vc_column_text css=&#8220;.vc_custom_1632216210586{margin-bottom: 0px !important;}&#8220;]<strong>Therapeutisches Drug Monitoring (TDM) f\u00fcr das Biologikum Vedolizumab stand bisher nicht im Fokus. Vedolizumab wird f\u00fcr die Behandlung von entz\u00fcndlichen Darmerkrankungen eingesetzt. Am Mittwoch, 29. September, werden im Online-Seminar die neusten Studien vorgestellt. <\/strong><!--more-->[\/vc_column_text][vc_column_text css=&#8220;.vc_custom_1632216195469{margin-bottom: 0px !important;}&#8220;]\n<h4>Inhalt des Online-Seminars<\/h4>\n<p>In den letzten Jahren kamen neue Biologika f\u00fcr die Behandlung von entz\u00fcndlichen Darmerkrankungen auf den Markt z. B. Vedolizumab, Entyvio\u00ae.<\/p>\n<p>Die therapeutische Arzneimittel\u00fcberwachung konzentrierte sich bisher vor allem auf Infliximab und Adalimumab, aber was ist mit Vedolizumab? Hier schlie\u00dft das Online-Seminar die L\u00fccke, gibt ein Update und stellt neue Informationen zu TDM f\u00fcr Vedolizumab vor.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner width=&#8220;2\/3&#8243;][vc_column_text css=&#8220;.vc_custom_1632207135678{margin-bottom: 0px !important;}&#8220;]\n<h4>Sprecher<\/h4>\n<p>Dr. Niels Vande Casteele, au\u00dferordentlicher Professor f\u00fcr Medizin an der UCSD, University of California in San Diego, wird Sie \u00fcber die Anwendung von TDM bei Vedolizumab informieren. Vande Casteele war der leitende Pr\u00fcfarzt der ERELATE-Studie, einer Beobachtungsstudie mit populationspharmakokinetischer Modellierung zur Bewertung der Expositions-Wirkungs-Beziehung von Vedolizumab bei entz\u00fcndlichen Darmerkrankungen (Vande Casteele N, et al. United European Gastroenterol J 2020;8 (Suppl 1):403.)[\/vc_column_text][\/vc_column_inner][vc_column_inner width=&#8220;1\/3&#8243;][vc_empty_space height=&#8220;16px&#8220;][mk_image src=&#8220;https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2020\/09\/niels-vande-casteele_photo-2.jpg&#8220; image_size=&#8220;full&#8220;][\/vc_column_inner][\/vc_row_inner][vc_row_inner][vc_column_inner][vc_column_text css=&#8220;.vc_custom_1632216174572{margin-bottom: 0px !important;}&#8220;]\n<h4>Zielgruppe<\/h4>\n<p>Das Online-Seminar richtet sich an alle, die sich f\u00fcr TDM interessieren: Kliniker wie Gastroenterologen, Dermatologen, Apotheker, Labor\u00e4rzte, Labortechniker sowie Gastro-Krankenschwestern.[\/vc_column_text][\/vc_column_inner][\/vc_row_inner][vc_cta h2=&#8220;&#8220; shape=&#8220;square&#8220; add_button=&#8220;bottom&#8220; btn_title=&#8220;Jetzt registrieren&#8220; btn_style=&#8220;classic&#8220; btn_shape=&#8220;square&#8220; btn_color=&#8220;inverse&#8220; btn_link=&#8220;url:https%3A%2F%2Fdevclinical.r-biopharm.com%2Fonline-seminars%2Ftherapeutic-drug-monitoring-for-vedolizumab-an-update%2F|target:_blank|&#8220;]Wir laden Sie ein, an der englischsprachigen Online-Pr\u00e4sentation teilzunehmen, die am Mittwoch, den 29. September um 16 Uhr (MEZ) stattfindet.[\/vc_cta][\/vc_column][\/vc_row]\n<\/div>","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_row_inner][vc_column_inner][vc_column_text css=&#8220;.vc_custom_1632216210586{margin-bottom: 0px !important;}&#8220;]Therapeutisches Drug Monitoring (TDM) f\u00fcr das Biologikum Vedolizumab stand bisher nicht im Fokus. Vedolizumab wird f\u00fcr die Behandlung von entz\u00fcndlichen Darmerkrankungen eingesetzt. Am Mittwoch, 29. September, werden im Online-Seminar die neusten Studien vorgestellt.<\/p>\n","protected":false},"author":1,"featured_media":155988,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"content-type":"","_relevanssi_hide_post":"","_relevanssi_hide_content":"","_relevanssi_pin_for_all":"","_relevanssi_pin_keywords":"","_relevanssi_unpin_keywords":"","_relevanssi_related_keywords":"","_relevanssi_related_include_ids":"","_relevanssi_related_exclude_ids":"","_relevanssi_related_no_append":"","_relevanssi_related_not_related":"","_relevanssi_related_posts":"","_relevanssi_noindex_reason":"","footnotes":""},"categories":[252],"tags":[],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.9 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8<\/title>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"de_DE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"og:description\" content=\"[vc_row][vc_column][vc_row_inner][vc_column_inner][vc_column_text css=&#8220;.vc_custom_1632216210586{margin-bottom: 0px !important;}&#8220;]Therapeutisches Drug Monitoring (TDM) f\u00fcr das Biologikum Vedolizumab stand bisher nicht im Fokus. Vedolizumab wird f\u00fcr die Behandlung von entz\u00fcndlichen Darmerkrankungen eingesetzt. Am Mittwoch, 29. September, werden im Online-Seminar die neusten Studien vorgestellt.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-22T09:09:51+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-09-22T09:09:46+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2021\/09\/2021-08_news-website_tdm-online-seminar.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"690\" \/>\n\t<meta property=\"og:image:height\" content=\"252\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"marc\" \/>\n<meta name=\"twitter:label1\" content=\"Verfasst von\" \/>\n\t<meta name=\"twitter:data1\" content=\"marc\" \/>\n\t<meta name=\"twitter:label2\" content=\"Gesch\u00e4tzte Lesezeit\" \/>\n\t<meta name=\"twitter:data2\" content=\"1\u00a0Minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/\",\"url\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/\",\"name\":\"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"isPartOf\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\"},\"datePublished\":\"2021-09-22T09:09:51+00:00\",\"dateModified\":\"2021-09-22T09:09:46+00:00\",\"author\":{\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/a2ebc752df58454eb54274e18b9ff168\"},\"breadcrumb\":{\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/#breadcrumb\"},\"inLanguage\":\"de\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/devclinical.r-biopharm.com\/de\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#website\",\"url\":\"https:\/\/devdevclinical.r-biopharm.com\/\",\"name\":\"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8\",\"description\":\"A Division of the R-Biopharm Group\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"de\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/a2ebc752df58454eb54274e18b9ff168\",\"name\":\"marc\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"de\",\"@id\":\"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/2c966fd42af84b698342eb122ef48788?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/2c966fd42af84b698342eb122ef48788?s=96&d=mm&r=g\",\"caption\":\"marc\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"de_DE","og_type":"article","og_title":"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","og_description":"[vc_row][vc_column][vc_row_inner][vc_column_inner][vc_column_text css=&#8220;.vc_custom_1632216210586{margin-bottom: 0px !important;}&#8220;]Therapeutisches Drug Monitoring (TDM) f\u00fcr das Biologikum Vedolizumab stand bisher nicht im Fokus. Vedolizumab wird f\u00fcr die Behandlung von entz\u00fcndlichen Darmerkrankungen eingesetzt. Am Mittwoch, 29. September, werden im Online-Seminar die neusten Studien vorgestellt.","og_url":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/","og_site_name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","article_published_time":"2021-09-22T09:09:51+00:00","article_modified_time":"2021-09-22T09:09:46+00:00","og_image":[{"width":690,"height":252,"url":"https:\/\/devclinical.r-biopharm.com\/wp-content\/uploads\/2021\/09\/2021-08_news-website_tdm-online-seminar.jpg","type":"image\/jpeg"}],"author":"marc","twitter_misc":{"Verfasst von":"marc","Gesch\u00e4tzte Lesezeit":"1\u00a0Minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/","url":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/","name":"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab - \ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","isPartOf":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#website"},"datePublished":"2021-09-22T09:09:51+00:00","dateModified":"2021-09-22T09:09:46+00:00","author":{"@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/a2ebc752df58454eb54274e18b9ff168"},"breadcrumb":{"@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/#breadcrumb"},"inLanguage":"de","potentialAction":[{"@type":"ReadAction","target":["https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/devclinical.r-biopharm.com\/de\/news\/update-therapeutisches-drug-monitoring-fuer-vedolizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/devclinical.r-biopharm.com\/de\/"},{"@type":"ListItem","position":2,"name":"Update: Therapeutisches Drug Monitoring f\u00fcr Vedolizumab"}]},{"@type":"WebSite","@id":"https:\/\/devdevclinical.r-biopharm.com\/#website","url":"https:\/\/devdevclinical.r-biopharm.com\/","name":"\ud83d\udea8\ud83d\udea8\ud83d\udea8 Staging!!! Clinical Diagnostics \ud83d\udea8\ud83d\udea8\ud83d\udea8","description":"A Division of the R-Biopharm Group","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/devdevclinical.r-biopharm.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"de"},{"@type":"Person","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/a2ebc752df58454eb54274e18b9ff168","name":"marc","image":{"@type":"ImageObject","inLanguage":"de","@id":"https:\/\/devdevclinical.r-biopharm.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/2c966fd42af84b698342eb122ef48788?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/2c966fd42af84b698342eb122ef48788?s=96&d=mm&r=g","caption":"marc"}}]}},"_links":{"self":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/155991"}],"collection":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/comments?post=155991"}],"version-history":[{"count":5,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/155991\/revisions"}],"predecessor-version":[{"id":155999,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/posts\/155991\/revisions\/155999"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media\/155988"}],"wp:attachment":[{"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/media?parent=155991"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/categories?post=155991"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/devclinical.r-biopharm.com\/de\/wp-json\/wp\/v2\/tags?post=155991"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}